UroGen Pharma Q2 2024: Assets $614K, Liabilities $65K

Ticker: URGN · Form: 10-Q · Filed: 2024-08-13T00:00:00.000Z

Sentiment: neutral

Topics: 10-Q, financials, pharmaceuticals

TL;DR

UroGen Pharma Q2: Assets $614K, Liabilities $65K. Raw materials $0.3M, prepaid $2.8M.

AI Summary

UroGen Pharma Ltd. filed its 10-Q for the period ending June 30, 2024. The company reported total assets of $614,035 and total liabilities of $65,212 for the quarter. They also disclosed $0.3 million in raw materials as non-current assets and $2.8 million in prepaid forward obligations as current liabilities.

Why It Matters

This filing provides a snapshot of UroGen Pharma's financial health and operational status for the second quarter of 2024, impacting investor decisions.

Risk Assessment

Risk Level: low — The filing is a routine quarterly report with no immediate red flags or significant negative events indicated.

Key Numbers

Key Players & Entities

FAQ

What were UroGen Pharma's total assets and liabilities as of June 30, 2024?

As of June 30, 2024, UroGen Pharma reported total assets of $614,035 and total liabilities of $65,212.

How much in raw materials did UroGen Pharma have classified as non-current assets on June 30, 2024?

UroGen Pharma had $0.3 million of raw materials included within other non-current assets on June 30, 2024.

What was the amount of prepaid forward obligation classified as current liabilities on June 30, 2024?

The amount paid and payable for the prepaid forward obligation included as current portion within other current liabilities was $2.8 million as of June 30, 2024.

What is the fiscal year end for UroGen Pharma?

UroGen Pharma's fiscal year ends on December 31.

What is the SIC code for UroGen Pharma?

The Standard Industrial Classification (SIC) code for UroGen Pharma is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 4,461 words · 18 min read · ~15 pages · Grade level 15.7 · Accepted 2024-08-13 08:05:44

Filing Documents

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Shareholders ' Equity (Deficit ) 3 Condensed Consolidated Statements of Cash Flows 5 Notes to Unaudited Condensed Consolidated Financial Statements 6 Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 33 Item 4.

Controls and Procedures

Controls and Procedures 35 PART II. OTHER INFORMATION 36 Item 1.

Legal Proceedings

Legal Proceedings 36 Item 1A.

Risk Factors

Risk Factors 36 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 81 Item 3. Defaults Upon Senior Securities 81 Item 4. Mine Safety Disclosures 81 Item 5. Other Information 81 Item 6. Exhibits 82

Signatures

Signatures 83 Trademarks and Trade Names Unless the context requires otherwise, references in this Quarterly Report to the "Company," "UroGen," "we," "us" and "our" refer to UroGen Pharma Ltd. and its subsidiary, UroGen Pharma, Inc. UroGen , RTGel , and Jelmyto are trademarks of ours that we use in this Quarterly Report. This Quarterly Report also includes trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this Quarterly Report appear without the or symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to our trademark and tradenames. We do not intend our use or display of other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. i Table of Contents

— Financial Information

Part I — Financial Information

Financial Statements

Item 1. Financial Statements. UroGen Pharma Ltd. Condensed Consolidated Balance Sheets (unaudited; in thousands, except share amounts and par value) June 30, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 219,972 $ 95,002 Marketable securities 21,106 41,966 Restricted cash 825 821 Accounts receivable, net 17,415 15,443 Inventories 7,442 5,673 Prepaid expenses and other current assets 12,208 10,281 Total current assets 278,968 169,186 Non-current assets: Property and equipment, net 580 689 Restricted deposit 175 225 Right of use assets 1,250 1,671 Marketable securities 203 4,502 Other non-current assets 673 2,038 Total Assets $ 281,849 $ 178,311 Liabilities and Shareholders' Equity (Deficit) Current liabilities: Accounts payable and accrued expenses $ 23,754 $ 16,538 Employee related accrued expenses 6,849 10,814 Other current liabilities 3,620 3,860 Total current liabilities: 34,223 31,212 Non-current liabilities: Prepaid forward obligation 115,880 109,722 Long-term debt 97,813 98,551 Long-term lease liabilities 425 844 Uncertain tax positions liability 3,194 3,194 Total Liabilities 251,535 243,523 Commitments and Contingencies (Note 18) Shareholders' Equity (Deficit): Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at June 30, 2024 and December 31, 2023; 41,169,954 and 32,490,119 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 112 89 Additional paid-in capital 775,270 614,035 Accumulated deficit ( 745,037 ) ( 679,348 ) Accumulated other comprehensive income (loss) ( 31 ) 12 Total Shareholders' Equity (Deficit) 30,314 ( 65,212 ) Total Liabilities and Shareholders' Equity (Deficit) $ 281,849 $ 178,311 The accompanying notes are an integral part of these condensed consolidated financial statements. 1 Table of Contents UroGen Pharma Ltd. Condensed Consolidated Statements of

View on Read The Filing